244 related articles for article (PubMed ID: 19103471)
1. HDAC expression and clinical prognosis in human malignancies.
Weichert W
Cancer Lett; 2009 Aug; 280(2):168-76. PubMed ID: 19103471
[TBL] [Abstract][Full Text] [Related]
2. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
3. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
4. Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.
Krusche CA; Vloet AJ; Classen-Linke I; von Rango U; Beier HM; Alfer J
Hum Reprod; 2007 Nov; 22(11):2956-66. PubMed ID: 17728353
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
6. Expression profile of class I histone deacetylases in human cancer tissues.
Nakagawa M; Oda Y; Eguchi T; Aishima S; Yao T; Hosoi F; Basaki Y; Ono M; Kuwano M; Tanaka M; Tsuneyoshi M
Oncol Rep; 2007 Oct; 18(4):769-74. PubMed ID: 17786334
[TBL] [Abstract][Full Text] [Related]
7. Isoform-specific histone deacetylase inhibitors: the next step?
Balasubramanian S; Verner E; Buggy JJ
Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
[TBL] [Abstract][Full Text] [Related]
8. HDAC family: What are the cancer relevant targets?
Witt O; Deubzer HE; Milde T; Oehme I
Cancer Lett; 2009 May; 277(1):8-21. PubMed ID: 18824292
[TBL] [Abstract][Full Text] [Related]
9. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Thomas S; Munster PN
Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
[TBL] [Abstract][Full Text] [Related]
11. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
Weichert W; Röske A; Gekeler V; Beckers T; Ebert MP; Pross M; Dietel M; Denkert C; Röcken C
Lancet Oncol; 2008 Feb; 9(2):139-48. PubMed ID: 18207460
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
13. SIRTUIN 1: regulating the regulator.
Zschoernig B; Mahlknecht U
Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
[TBL] [Abstract][Full Text] [Related]
14. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P
Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme I; Deubzer HE; Wegener D; Pickert D; Linke JP; Hero B; Kopp-Schneider A; Westermann F; Ulrich SM; von Deimling A; Fischer M; Witt O
Clin Cancer Res; 2009 Jan; 15(1):91-9. PubMed ID: 19118036
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
18. The development and potential clinical utility of biomarkers for HDAC inhibitors.
Shi B; Xu W
Drug Discov Ther; 2013 Aug; 7(4):129-36. PubMed ID: 24071574
[TBL] [Abstract][Full Text] [Related]
19. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
Fritzsche FR; Weichert W; Röske A; Gekeler V; Beckers T; Stephan C; Jung K; Scholman K; Denkert C; Dietel M; Kristiansen G
BMC Cancer; 2008 Dec; 8():381. PubMed ID: 19099586
[TBL] [Abstract][Full Text] [Related]
20. N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
Giannini G; Marzi M; Pezzi R; Brunetti T; Battistuzzi G; Marzo MD; Cabri W; Vesci L; Pisano C
Bioorg Med Chem Lett; 2009 Apr; 19(8):2346-9. PubMed ID: 19285395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
